L&K Biomed Ltd. (KOSDAQ:156100)
South Korea
· Delayed Price · Currency is KRW 10,070
-260 (-2.52%)
At close: Mar 6, 2026
L&K Biomed Revenue
L&K Biomed had revenue of 10.10B KRW in the quarter ending September 30, 2025, with 3.59% growth. This brings the company's revenue in the last twelve months to 40.33B, up 21.55% year-over-year. In the year 2024, L&K Biomed had annual revenue of 36.09B with 20.69% growth.
Revenue (ttm)
40.33B
Revenue Growth
+21.55%
P/S Ratio
5.54
Revenue / Employee
399.36M
Employees
101
Market Cap
223.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.09B | 6.19B | 20.69% |
| Dec 31, 2023 | 29.90B | 10.14B | 51.28% |
| Dec 31, 2022 | 19.77B | 4.39B | 28.59% |
| Dec 31, 2021 | 15.37B | -3.98B | -20.58% |
| Dec 31, 2020 | 19.36B | -7.22B | -27.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MEDIANA Co.,Ltd | 59.83B |
| SELVAS Healthcare | 29.79B |
| ASTERASYS Co.,Ltd | 36.47B |
| Remed | 24.26B |
| Noul Co.,Ltd. | 3.91B |
| Next Biomedical | 14.90B |
| QuantaMatrix | 3.35B |
| Hironic | 33.18B |